Commission fines pharmaceutical companies for drug-delay deals

Promoted content

The European Commission on Wednesday imposed fines totaling €427.7 million on the French pharmaceutical company Servier and five producers of generic medicines – Niche/Unichem, Matrix (now part of Mylan), Teva, Krka and Lupin – for concluding a series of deals of deals all aimed at protecting Servier’s bestselling blood pressure medicine, perindopril, from price competition by generics in the EU.

Through a technology acquisition and a series of patent settlements with generic rivals, Servier implemented a strategy to exclude competitors and delay the entry of cheaper generic medicine to the detriment of public budgets and patients in breach of EU antitrust rules.

Subscribe to our newsletters

Subscribe